Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors

NCT04611711 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Patients With Digestive System Tumors Resistant to PD-1 Inhibitors

Interventions

DRUG: decitabine＋ TQB2450 injection
DRUG: decitabine＋ TQB2450 injection＋Anlotinib

Sponsor

Peking University